Evidence map›Paper›PMID 39914654›Full record

ArticleKidney international2025

A kidney organoid-based readout to assess disease activity in primary and recurrent focal segmental glomerulosclerosis.

Ashwani Kumar Gupta, Ekta Minocha, Kyle M Koss, Bilal A Naved, Luisa Safar-Boueri, Jason A Wertheim, Lorenzo Gallon

Abstract read
In one paragraph

Article in Kidney international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Serum Factors in Primary Podocytopathies.Antibodies (Basel, Switzerland) · 2025
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ashwani Kumar GuptaDepartment of Surgery, University of Arizona College of Medicine, Tucson, Arizona, USA; Bio5 Institute, University of Arizona, Tucson, Arizona, USA; Surgery Service, Southern Arizona Veterans Affairs Health Care System, Tucson, Arizona, USA; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Ekta MinochaDepartment of Surgery, University of Arizona College of Medicine, Tucson, Arizona, USA; Bio5 Institute, University of Arizona, Tucson, Arizona, USA; Surgery Service, Southern Arizona Veterans Affairs Health Care System, Tucson, Arizona, USA.
Kyle M KossDepartment of Surgery, University of Arizona College of Medicine, Tucson, Arizona, USA; Bio5 Institute, University of Arizona, Tucson, Arizona, USA; Surgery Service, Southern Arizona Veterans Affairs Health Care System, Tucson, Arizona, USA; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Department of Neurobiology, University of Texas Medical Branch, Galveston, Texas, USA; Sealy Institute for Drug Discovery, University of Texas Medical Branch, Galveston, Texas, USA.
Bilal A NavedDepartment of Biomedical Engineering, Northwestern University, Evanston, Illinois, USA.
Luisa Safar-BoueriDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Jason A WertheimDepartment of Surgery, University of Arizona College of Medicine, Tucson, Arizona, USA; Bio5 Institute, University of Arizona, Tucson, Arizona, USA; Surgery Service, Southern Arizona Veterans Affairs Health Care System, Tucson, Arizona, USA; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Department of Biomedical Engineering, Northwestern University, Evanston, Illinois, USA; Department of Biomedical Engineering, University of Arizona, Tucson, Arizona, USA. Electronic address: jwertheim@arizona.edu.
Lorenzo GallonDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Department of Medicine, Abdominal Organ Transplant Program, University of Illinois Chicago, Chicago, Illinois, USA. Electronic address: lgallon@uic.edu.

Funding

Repairing the Kidney Endothelium via Targeted Extracellular Matrix ModifiersR01DK113168 · NIDDK · UNIVERSITY OF ARIZONA · PI WERTHEIM, JASON A · 2018 to 2022
$1.6M
NIDDK NIH HHS R01 DK113168
6 · The paper itself

Abstract

Primary focal segmental glomerulosclerosis (pFSGS) is an acquired kidney disorder that frequently leads to kidney failure and confers an elevated risk of recurrence after kidney transplantation, termed recurrent pFSGS. Unfortunately, there is no diagnostic method to foresee recurrence of pFSGS after kidney transplantation. Progress in developing assays to test disease activity is hampered by few preclinical models to replicate disease and inability of in vitro cultured primary podocytes to remain terminally differentiated. In recent years, advancements in kidney organoid biology have led to the development of kidney tissues with glomeruli and major nephron segments including podocytes. To develop a pFSGS model, we studied the effect of plasma from patients diagnosed with pFSGS on kidney organoids differentiated from human pluripotent stem cells. The pFSGS plasma treatment induced podocytopathy, extracellular matrix protein deposition, fibrosis and apoptosis within organoids, whereas non-recurrent plasma did not affect organoid structure. pFSGS plasma also led to loss of normal expression patterns of podocyte specific proteins, nephrin and podocin within podocytes. Further, cytokine array profiling revealed that pFSGS plasma induced secretion of cytokines associated with inflammation and angiogenesis. Additionally, kidney organoids treated with plasma obtained after therapeutic plasma exchange for recurrent pFSGS led to lower cell death in organoids after sequential exchanges with the final exchange showing the least apoptotic cells without morphological abnormality. Overall, our results demonstrate the potential of kidney organoids in advancing kidney disease modeling. These insights could be applied in clinical settings to assist in gauging FSGS recurrence risk prior to kidney transplantation.

Indexed as

Glomerulosclerosis, Focal SegmentalOrganoidsPodocytesApoptosisCells, CulturedCytokinesHumansIntracellular Signaling Peptides and ProteinsMembrane ProteinsPluripotent Stem CellsRecurrenceCytokinesIntracellular Signaling Peptides and ProteinsMembrane ProteinsnephrinNPHS2 proteinextracellular matrixglomerulushuman plasmakidney organoidspodocytesprimary focal segmental glomerulosclerosis

Identifiers

PMID39914654
PMCPMC13283730

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.